This is a randomized double blind placebo-controlled study that will assess the efficacy of Tamsulosin oral-controlled absorption system (OCAS) 0.4 mg in the conjunctive medical treatment of distal ureteral stones with a size of 4-10 mm compared to placebo in control group.

• patient will be randomized to receive placebo or Tamsulosin OCAS 0.4 mg 1 tablet OD for a maximum of 28 days or until the ureteral stone is passed and sodium diclofenac 50 mg twice a day, for 10 days.
• All patients will receive 75 mg sodium diclofenac via intramuscular on demand

Inclusion Criteria:

• Male or female patient aged => 18 years.
• Patients who have distal ureteral stones with a size of 4-10 mm
• Written informed consent has been obtained.

Exclusion Criteria:

• Patients with history of ureteral surgery
• Patients with urinary tract infection
• Patient with diabetes and peptic ulcer
• Patient with renal dysfunction (elevated of serum creatinine level)
• Patients with severe hydronephrosis
• Patients with history of passing stones
• Pregnancy
• Patients who desire to withdraw from the study